


REQUEST FOR ACCESS OF ABANDONED APPLICATION UNDER 37 CFR 1.14(a)



In re Application of

Hemp et al

Application Number

07/098114

Filed

12/29/1992

Group Art Unit

Examiner

Paper No. *15*

Assistant Commissioner for Patents
Washington, DC 20231

I hereby request access under 37 CFR 1.14(a)(3)(iv) to the application file record of the above-identified ABANDONED application, which is: (CHECK ONE):

☒ (A) referred to in United States Patent Number 5674882, column _____.

☐ (B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.11, i.e., Application No. _____, filed _____, on page _____ of paper number _____.

☐ (C) an application that claims the benefit of the filing date of an application that is open to public inspection, i.e., Application No. _____, filed _____, or

☐ (D) an application in which the applicant has filed an authorization to lay open the complete application to the public.

Please direct any correspondence concerning this request to the following address:

Harvey Gore

Signature

2/26/2001

Date

Harvey Gore

Typed or printed name

FOR PTO USE ONLY

Approved by: *[Signature]*

(initials)

Unit: *FTU*

United States Patent [19]**Kempf et al.**[11] **Patent Number:** **5,674,882**[45] **Date of Patent:** **Oct. 7, 1997**[54] **RETROVIRAL PROTEASE INHIBITING COMPOUNDS**[75] **Inventors:** Dale J. Kempf, Libertyville; Daniel W. Norbeck, Crystal Lake; Hing Leung Sham; Chen Zhao, both of Gurnee, all of Ill.[73] **Assignee:** Abbott Laboratories, Abbott Park, Ill.[21] **Appl. No.:** 413,136[22] **Filed:** Mar. 29, 1995**Related U.S. Application Data**


[60] Division of Ser. No. 158,587, Dec. 2, 1993, abandoned, which is a continuation-in-part of Ser. No. 998,114, Dec. 29, 1992, abandoned, which is a continuation-in-part of Ser. No. 777,626, Oct. 23, 1991, which is a continuation-in-part of Ser. No. 746,020, Aug. 15, 1991, abandoned, which is a continuation-in-part of Ser. No. 616,170, Nov. 20, 1990, abandoned, which is a continuation-in-part of Ser. No. 518,730, May 9, 1990, Pat. No. 5,142,056, which is a continuation-in-part of Ser. No. 456,124, Dec. 22, 1989, abandoned, which is a continuation-in-part of Ser. No. 405,604, Sep. 8, 1989, abandoned, which is a continuation-in-part of Ser. No. 355,945, May 23, 1989, abandoned.

[51] **Int. Cl.⁶** **A61K 31/41**[52] **U.S. Cl.** **514/365; 514/374**[58] **Field of Search** 514/365, 374[56] **References Cited****U.S. PATENT DOCUMENTS**

4,172,094	10/1979	Dybas et al.	544/396
4,618,619	10/1986	Regel et al.	514/383
4,644,055	2/1987	Ketner et al.	530/330
4,652,552	3/1987	Ketner et al.	514/18
5,142,056	8/1992	Kempf et al.	546/265
5,354,866	10/1994	Kempf et al.	546/265

Primary Examiner—Russell Travers*Attorney, Agent, or Firm*—Steven R. Crowley[57] **ABSTRACT**

A retroviral protease inhibiting compound of the formula:



is disclosed.

3 Claims, No Drawings